Significance StatementAlmost 4 decades of laboratory research have shown safety and efficacy of stem cells in stroke animals. Yet, this cell‐based regenerative medicine remains designated as "experimental" in the clinic. Equally disappointing, two recently concluded clinical trials indicated stem cells are safe but not effective in stroke patients. These failed clinical trials may be due to a loss in translation of optimal laboratory stem cell transplantation protocols to clinical trial designs. A concerted effort between basic scientists and clinicians, with NIH and Food and Drug Administration guidance, is key to realizing the safe and effective translation of stem cell therapy for stroke.

Stem Cell Therapy for Stroke Has Reached Clinical Trials. The Long Wait Is Over! Or Is the Wait Still On? {#sct312521-sec-0003}
=========================================================================================================

In the late 1980s, Sharp and colleagues ushered one of the pioneering laboratory investigations in cell therapy for stroke, demonstrating the survival of rat fetal neocortical grafts in ischemic adult rat cortex [1](#sct312521-bib-0001){ref-type="ref"}, [2](#sct312521-bib-0002){ref-type="ref"}. Subsequent studies showed that these grafted fetal cells integrated with the ischemic brain received afferent fibers and vascularization from the host intact tissue [3](#sct312521-bib-0003){ref-type="ref"}, [4](#sct312521-bib-0004){ref-type="ref"} and responded to contralateral sensory stimulation with increased metabolic activity [5](#sct312521-bib-0005){ref-type="ref"}. Equally promising are the observations that stroke animals transplanted with fetal striatal cells into the ischemic striatum displayed some improvements in a simple cognitive task of passive avoidance [6](#sct312521-bib-0006){ref-type="ref"}, as well as in a more complex water maze learning test [7](#sct312521-bib-0007){ref-type="ref"}.

Over the next 4 decades of preclinical research, additional evidence of graft survival, migration, differentiation, and functional integration in the ischemic brain, modest anatomical reconstruction, and remodeling of brain circuitry, neurochemical, physiological, and behavioral recovery have been documented [2](#sct312521-bib-0002){ref-type="ref"}, [8](#sct312521-bib-0008){ref-type="ref"}. Several mechanisms have also been postulated to mediate the therapeutic effects of cell transplants in stroke; although initially designed as a cell replacement for dead or ischemic cells, the current view puts robust by‐stander effects of the grafted cells to secrete therapeutic substances [9](#sct312521-bib-0009){ref-type="ref"}, [10](#sct312521-bib-0010){ref-type="ref"}, [11](#sct312521-bib-0011){ref-type="ref"}, [12](#sct312521-bib-0012){ref-type="ref"}. The initial studies on human neuroteratocarcinoma cells were to convert these cells into postmitotic neuron‐like cells [13](#sct312521-bib-0013){ref-type="ref"}. Subsequent studies on embryonic stem cells [14](#sct312521-bib-0014){ref-type="ref"}, genetically engineered mesenchymal stem cells (MSCs; Sanbio, Mountain View, CA) [15](#sct312521-bib-0015){ref-type="ref"}, and fetal‐derived stem cells (by Reneuron, Bridgend, UK) [16](#sct312521-bib-0016){ref-type="ref"}, and even with the present modification of induced pluripotent stem cells (iPSCs) for stroke indication, still maintain the need to generate an ample amount of neuron‐like cells based on the notion that functional recovery can be achieved by repairing the neuronal synaptic circuitry via replenishing infarcted cells and ischemic cells with neuronal cells. The recognition that stroke not only affects neurons but also other neural cell types, especially vascular cells, prompted the search for alternative regenerative processes that rescue in tandem neural and vascular cells, under the theme of attenuating the impaired neurovascular unit [17](#sct312521-bib-0017){ref-type="ref"}. Toward stimulating these non‐neuronal repair processes, the stem cells\' by‐stander effects have been proposed, including the grafted cells\' ability to secrete substances that promote neurogenesis, angiogenesis, vasculogenesis, anti‐inflammation, among other therapeutic substances. Over the last 5 years, additional novel stem cell component‐based mechanisms have been demonstrated to accompany stem cell therapy, such as the transfer of stem cell‐derived mitochondria, exosomes, microvesicles, and micro‐RNAs into the ischemic area [18](#sct312521-bib-0018){ref-type="ref"}, [19](#sct312521-bib-0019){ref-type="ref"}, [20](#sct312521-bib-0020){ref-type="ref"}, [21](#sct312521-bib-0021){ref-type="ref"}, [22](#sct312521-bib-0022){ref-type="ref"}. Additionally, although stroke is traditionally considered a brain disorder, the role of peripheral organs, such as the spleen and the gut, has been implicated in the disease pathology, and that sequestration of their aberrant inflammatory and microbiome response has been deemed therapeutic, which can be achieved with stem cell transplantation [19](#sct312521-bib-0019){ref-type="ref"}, [23](#sct312521-bib-0023){ref-type="ref"}. With these regenerative mechanisms ascribed to stem cells, developing them into stem cell release criteria would enhance the quality control screening of viable and transplantable cells that would ensure therapeutic potency following their transplantation into the stroke brain. One could also envision using these potency assays as indices of stem cell functional status during the poststroke transplantation period, in that one can monitor the levels of growth factors, inflammation, mitochondrial function, splenic function, and gut microbiota both centrally and peripherally. Thus, in addition to phenotypic markers of stemness and the optimal transplant regimen (i.e., dose, timing, and route of delivery), adding these potency assays will likely improve the clinical outcomes of stem cell therapy for stroke.

These important basic science experiments have laid the groundwork for advancing cell therapy for stroke to the clinic. Recognizing that same species allogeneic transplantation (i.e., from rat‐to‐rat cell‐donor‐transplant recipient to human‐to‐human cell‐donor‐transplant recipient) may provide safe and effective treatment for the envisioned clinical trial, the search for transplantable human cells became paramount to realize translation of cell therapy from the laboratory to the clinic. The use of fetal cells poses ethical and logistical challenges. A moratorium in the 1990s on the use of federal funds for embryonic stem cell research, and with iPSCs still not yet available at that time, nullified pursuing these tissue sources for clinical cell therapy. The first human clinical trial using human neuroteratocarcinoma cells transformed into postmitotic neurons transplanted into stroke patients was performed in 1998 [24](#sct312521-bib-0024){ref-type="ref"} based on our earlier preclinical work [13](#sct312521-bib-0013){ref-type="ref"}. Financial strain to the company sponsor of these neuroteratocarcinoma cells contributed to abandoning this clinical trial, prompting the search for alternative transplantable cells. Adult tissue‐derived stem cells, including those harvested from bone marrow, umbilical cord, and adipose, eventually took center stage and to date remain as the front‐runner cell source for cell therapy for stroke [25](#sct312521-bib-0025){ref-type="ref"}, [26](#sct312521-bib-0026){ref-type="ref"}, [27](#sct312521-bib-0027){ref-type="ref"}.

Primarily because of the long‐track record of solid safety profile, the bone marrow has emerged as the widely used adult tissue stem cell source [26](#sct312521-bib-0026){ref-type="ref"}, [28](#sct312521-bib-0028){ref-type="ref"}, [29](#sct312521-bib-0029){ref-type="ref"}, [30](#sct312521-bib-0030){ref-type="ref"}, [31](#sct312521-bib-0031){ref-type="ref"}, [32](#sct312521-bib-0032){ref-type="ref"}. Bone marrow‐derived cell populations as well as engineered stem/progenitor cells have been characterized, including but not limited to MSCs, mononuclear cells (MNCs), endothelial progenitor cells, SB623, multipotent adult progenitor cells (MAPCs), and multilineage‐differentiating stress‐enduring cells (Muse) [33](#sct312521-bib-0033){ref-type="ref"}, [34](#sct312521-bib-0034){ref-type="ref"}, [35](#sct312521-bib-0035){ref-type="ref"}, [36](#sct312521-bib-0036){ref-type="ref"}, [37](#sct312521-bib-0037){ref-type="ref"}. These bone marrow‐derived stem cells have been widely examined in preclinical stroke models, revealing the cells\' ability to display multipotent cell properties in vitro [38](#sct312521-bib-0038){ref-type="ref"}, [39](#sct312521-bib-0039){ref-type="ref"}, [40](#sct312521-bib-0040){ref-type="ref"}, [41](#sct312521-bib-0041){ref-type="ref"}, [42](#sct312521-bib-0042){ref-type="ref"}, [43](#sct312521-bib-0043){ref-type="ref"} and to reduce behavioral and histological deficits after transplantation in vivo [44](#sct312521-bib-0044){ref-type="ref"}, providing solid basis for clinical trials. Autologous bone marrow MSCs when intravenously transplanted in patients at 4 weeks after stroke onset displayed no adverse effects and even improved neurological outcomes, but such efficacy declined by 12 months post‐transplantation [45](#sct312521-bib-0045){ref-type="ref"}. An open‐labeled trial of autologous transplantation of bone marrow MNCs intravenously delivered in patients within 24--72 hours poststroke was also safe and exerted better functional recovery that lasted for over 6 month post‐transplantation [46](#sct312521-bib-0046){ref-type="ref"}. However, a subsequent phase II, multicenter, parallel group, randomized, and blinded trial demonstrated that autologous bone marrow MNCs intravenously delivered at median of 18.5 days after stroke onset was again safe but did not result in functional improvement [47](#sct312521-bib-0047){ref-type="ref"}. Interestingly, another open‐labeled trial employing an intra‐arterial deliver of a subset of CD34+ bone marrow MNCs within 7 days of stroke onset was also shown to be safe with improved functional outcomes during the 6‐month post‐transplantation period [48](#sct312521-bib-0048){ref-type="ref"}. More recent clinical trials have reported mixed outcomes, in that while overwhelmingly safe, demonstrating the efficacy of stem cell therapy for stroke has failed in both the intravenous transplantation of MAPCs in acute stroke patients [49](#sct312521-bib-0049){ref-type="ref"} and the intracerebral transplantation of SB623 in chronic stroke patients [50](#sct312521-bib-0050){ref-type="ref"}, [51](#sct312521-bib-0051){ref-type="ref"}, [52](#sct312521-bib-0052){ref-type="ref"}.

Based on these interim clinical trials, transplantation of bone marrow stem cell derivatives, primarily MSCs and MNCs, is deemed safe for stroke, but their efficacy remains elusive. Conclusive interpretations of the clinical data are hindered by small number of enrolled patients and the open‐labeled approach in some of these trials. Moreover, vis‐a‐vis comparisons between these trials will be difficult because of different donor cells and varied clinical transplant protocols (Table [1](#sct312521-tbl-0001){ref-type="table"}). Phenotypic markers for MSCs include SH‐2 and SH‐4 [45](#sct312521-bib-0045){ref-type="ref"}; specific flow cytometric antibodies (CD3, CD14, CD16, CD19, CD20, CD34, CD45, CD56, Lin 1, CD133‐2) [46](#sct312521-bib-0046){ref-type="ref"}; or limited to CD34 and CD45 [47](#sct312521-bib-0047){ref-type="ref"}; or magnetic cell isolation procedures focused on CD34+ cells [48](#sct312521-bib-0048){ref-type="ref"}; MAPCs are defined as c‐Kit+, CD9+, CD13+, CD31+, CD44−, MHC‐I‐, CD45−, Thy1‐ [49](#sct312521-bib-0049){ref-type="ref"}, [53](#sct312521-bib-0053){ref-type="ref"}, while SB623 are Notched‐induced MSCs [15](#sct312521-bib-0015){ref-type="ref"}, [50](#sct312521-bib-0050){ref-type="ref"}, [51](#sct312521-bib-0051){ref-type="ref"}, [54](#sct312521-bib-0054){ref-type="ref"}, [55](#sct312521-bib-0055){ref-type="ref"}. Additionally, the therapeutic windows spanned from acute to chronic stroke stages, as well as routes of administration varied across trials [45](#sct312521-bib-0045){ref-type="ref"}, [46](#sct312521-bib-0046){ref-type="ref"}, [47](#sct312521-bib-0047){ref-type="ref"}, [48](#sct312521-bib-0048){ref-type="ref"}, [49](#sct312521-bib-0049){ref-type="ref"}, [50](#sct312521-bib-0050){ref-type="ref"}, [51](#sct312521-bib-0051){ref-type="ref"}.

###### 

Stem cell transplantation protocols for stroke therapy

  Reports                                                      Stem cell type   Route   Dose                 Timing
  ------------------------------------------------------------ ---------------- ------- -------------------- --------------
  Laboratory studies                                                                                         
  Mays et al. [59](#sct312521-bib-0059){ref-type="ref"}        MAPCs            i.c.    0.4 million          7 days
  Mays et al. [59](#sct312521-bib-0059){ref-type="ref"}        MAPCs            i.v.    4 million            1--7 days
  Acosta et al. [89](#sct312521-bib-0089){ref-type="ref"}      MSCs             i.v.    4 million            60 days
  Borlongan et al. [90](#sct312521-bib-0090){ref-type="ref"}   MSCs             i.c.    0.2 million          3 hours
  Clinical trials                                                                                            
  Bang et al. [45](#sct312521-bib-0045){ref-type="ref"}        MSCs             i.v.    100 million          4 weeks
  Savitz et al. [46](#sct312521-bib-0046){ref-type="ref"}      MNCs             i.v.    100 million          1--3 days
  Prasad et al. [47](#sct312521-bib-0047){ref-type="ref"}      MNCs             i.v.    280.75 million       18.5 days
  Banerjee et al. [48](#sct312521-bib-0048){ref-type="ref"}    HSCs             i.a.    100 million          7 days
  Hess et al. [49](#sct312521-bib-0049){ref-type="ref"}        MAPC             i.v.    400--1,200 million   24--48 hours
  Steinberg et al. [50](#sct312521-bib-0050){ref-type="ref"}   SB623            i.c.    2.5--10 million      6--60 months
  Hess et al. [60](#sct312521-bib-0060){ref-type="ref"}        MAPC             i.v.    1,200 million        18--36 hours
  Kalladka et al. [91](#sct312521-bib-0091){ref-type="ref"}    CTX‐DP           i.c.    2--20 million        6--60 months
  Lee et al. [92](#sct312521-bib-0092){ref-type="ref"}         MSCs             i.v.    50 million           4 weeks

Type of cells, route of administration, doses, and timing are listed.

Abbreviations: HSCs, hematopoietic stem cells; i.c., intracerebral; MAPCs, multipotent adult progenitor cells; MNCs, mononuclear cells; MSCs, mesenchymal stem cells.

A major contributor to the failure of clinical trials to reach efficacy endpoints is the translational discrepancy between the laboratory and clinical stem cell transplant protocols (Table [1](#sct312521-tbl-0001){ref-type="table"}). Efficacy readouts in the laboratory, which were achieved under strict cell dose and timing of transplantation windows, are not strictly followed in the clinic. The preclinical effective intravenous dose is around 4 million cells in a stroke rat weighing 250 g, which translates to approximately 840 million cells in a stroke patient weighing 75 kg [56](#sct312521-bib-0056){ref-type="ref"}, yet most clinical trials use doses well below this efficacious dose [45](#sct312521-bib-0045){ref-type="ref"}, [47](#sct312521-bib-0047){ref-type="ref"}, [48](#sct312521-bib-0048){ref-type="ref"}. Of note, stroke patients who received a dose that adhered to this preclinical cell dose displayed clinical improvements [46](#sct312521-bib-0046){ref-type="ref"}. In the same token, the intracerebral dose of 200,000 cells is efficacious in the stroke rat, which is equivalent to approximately 56 million cells in the stroke patient, but again the clinical doses (2.5 and 5 million cells) used were at least 10‐fold below this dose, which may explain the lack of efficacy [50](#sct312521-bib-0050){ref-type="ref"}, [51](#sct312521-bib-0051){ref-type="ref"}. The cell dose found effective in the stroke rat was correctly gated in the MAPC trial (400 to 1,200 million cells) [49](#sct312521-bib-0049){ref-type="ref"} but still did not reach efficacy [57](#sct312521-bib-0057){ref-type="ref"}. Post hoc analysis, however, revealed that those patients who received the MAPC transplants less than 36 hours exhibited functional improvements [58](#sct312521-bib-0058){ref-type="ref"}, which were predicted in the preclinical study [59](#sct312521-bib-0059){ref-type="ref"} and now the targeted therapeutic window in a subsequent MAPC trial [60](#sct312521-bib-0060){ref-type="ref"}. Strict adherence to the preclinical outcomes of optimal cell dose, timing, and route is a must if efficacy is to be achieved in the clinic.

Lab‐to‐clinic translation and the subsequent clinical trial design of stem cell therapy have emphasized the logistics and technical aspects of the transplant regimen and may have neglected the basic science discoveries that defined stemness properties and mechanisms of stem cells. The rule of thumb when contemplating any envisioned stem cell clinical product must consider a well‐defined set of phenotypic markers of the stem cells and a solid insight into their mode of action. Access to clinical‐grade stem cells should preclude a set of product release criteria of either homogenous population of cells or a consistent and reproducible generation of the same stem cell population. The clinical transplant regimen should also build upon the lessons learned from the laboratory about postulated mechanisms, including cell replacement, growth factor secretion, and promotion of endogenous brain repair processes [61](#sct312521-bib-0061){ref-type="ref"}, [62](#sct312521-bib-0062){ref-type="ref"}, [63](#sct312521-bib-0063){ref-type="ref"}, [64](#sct312521-bib-0064){ref-type="ref"}, [65](#sct312521-bib-0065){ref-type="ref"}, which may synergistically work together to combat the multipronged cell death pathways associated with stroke [66](#sct312521-bib-0066){ref-type="ref"}, [67](#sct312521-bib-0067){ref-type="ref"}, [68](#sct312521-bib-0068){ref-type="ref"}. In view of this intricate stroke‐induced cell death cascade, stem cell therapy may be optimized not as a stand‐alone treatment but as a combination therapy with tissue Plasminogen Activator (tPA), other neuroprotective drugs, biomaterials [69](#sct312521-bib-0069){ref-type="ref"}, or thrombectomy (see below), as well as with standard stroke care management involving rehabilitation [70](#sct312521-bib-0070){ref-type="ref"}, [71](#sct312521-bib-0071){ref-type="ref"}.

Although efficacy in preclinical stroke models is paramount toward moving the stem cell product to the clinic, equally important is establishing the safety profile of the stem cells, such as their proliferative, tumorgeneic or ectopic tissue formation capacity, persistence specifically tissue or organ deposition, and cell fate following transplantation into the stroke brain. The differentiation of stem cells into a phenotype when lodged in a particular organ may elicit deleterious immune response or inflammatory reaction that can be toxic or can elicit tumorigenesis. Ample consideration should also be given when using genetically engineered stem cells, such as SB623 or immortalized cells such as CTX03 [26](#sct312521-bib-0026){ref-type="ref"}, [30](#sct312521-bib-0030){ref-type="ref"}. With the notion that stem cells may confer therapeutic effects via secreted substances, there is also a translational push favoring decellularized over cellularized compositions, and such pharmacologic‐like or cell‐free treatments may benefit from the translational Stroke Treatment Academic Industry Roundtable (STAIR) criteria toward achieving the neuroprotective drug\'s safety profile [72](#sct312521-bib-0072){ref-type="ref"}. Specific safety deliberations are necessary when using freshly harvested, cultured, or cryopreserved cells, naked, encapsulated, or extracellular matrix‐loaded cells, and novel delivery devices such as sustained, controlled, and highly regulated nanoparticles, exosomes, extracellular vesicles, microRNAs, mitochondria, and other cellular components [18](#sct312521-bib-0018){ref-type="ref"}, [20](#sct312521-bib-0020){ref-type="ref"}, [73](#sct312521-bib-0073){ref-type="ref"}, [74](#sct312521-bib-0074){ref-type="ref"}, [75](#sct312521-bib-0075){ref-type="ref"}, [76](#sct312521-bib-0076){ref-type="ref"}. The once cell‐directed transplantation approach has been replaced with much sophisticated cell components that have expanded toward emerging therapies using innovative cell‐derivative and even cell‐free compositions that will require a unique set of safety outcome evaluations.

If clinical entry of stem cell products is the desired goal, then the use of clinical‐grade stem cells from the get‐go would allow a more efficient entry of stem cells to the clinic. The rigid regulatory translational path of stem cell from the laboratory to the clinic provides no allowance for modification of the stem cell product. Developing clinical‐grade lines would require many changes to the original protocols, because the standards for manufacturing clinical biological agents are stricter than the standards for research‐grade cell lines, necessitating the need to find alternatives to the laboratory animal‐derived reagents that most likely are not allowed for clinical use [77](#sct312521-bib-0077){ref-type="ref"}. In the end, the Good Manufacturing Practice (GMP)‐manufactured stem cells are likely different from the laboratory‐grade stem cells, in that the phenotype and biological properties originally designed to treat a specific disease in the laboratory may now have a different disease indication in the clinic. Similarly, other cell manufacturing technical aspects may change the eventual stem cell product. Key cell product release criteria to the commercial and clinical application of stem cells are suitable cryopreservation protocols for long‐term storage, which may prove refractory for some stem cells [78](#sct312521-bib-0078){ref-type="ref"}. The expansion time and amplification process, including the matrices and reagents (e.g., serum or platelet lysate) under clinical GMP may generate MSCs that differ in their immunomodulatory properties [79](#sct312521-bib-0079){ref-type="ref"}, thereby affecting the cells\' therapeutic effects. Finally, because human stem cells are tested in animal models, this cross‐species paradigm likely will present with different safety and efficacy scenario in the same‐species clinical application. This would indicate that the risk profile of stem cell‐based products should consider the envisioned clinical product of autologous or allogeneic stem cells, including their differentiation status and proliferation capacity, the route of administration, the intended location, and long‐term survival of engrafted cells which will affect the clinical risks of tumor formation, unwanted immune responses, and the transmission of adventitious agents [80](#sct312521-bib-0080){ref-type="ref"}, and the clinical efficacy readouts. In the end, the theoretical or potential application of stem cells observed in animal studies should closely approximate the applied setting in the clinic if GMP‐certified stem cells were to replicate the safety and efficacy profile of the lab‐grade stem cells.

To this end, in support of allowing the basic science‐generated efficacy and safety readouts of stem cell transplantation in preclinical stroke to dictate the entry of this therapy to the clinic, a set of guidelines for translational research and clinical trial design has been recommended by a consortium of basic scientists, clinicians, industry partners, and NIH and Food and Drug Administration regulators under the consortium of Stem cell Therapeutics as an Emerging Paradigm for Stroke (STEPS). A collaborative effort among these stakeholders may provide an expeditious clinical entry of stem cell therapeutics. The overarching thesis of STEPS is that basic science should dictate the translation and eventual clinical application of stem cell therapy for stroke. Unfortunately, a careful examination of the literature reveals few studies adhering to these STEPS lab‐to‐clinic translational guidelines [81](#sct312521-bib-0081){ref-type="ref"}. The investigation of stem cell therapy in a clinically relevant setting, in particular assessing its efficacy and safety in direct comparison to rehabilitation, has not been fully examined [81](#sct312521-bib-0081){ref-type="ref"}.

In an effort to enhance successful translation of stroke therapeutics, a new NIH NINDS initiative called Stroke Preclinical Assessment Network (SPAN) program [82](#sct312521-bib-0082){ref-type="ref"} has solicited projects designed to evaluate the potential of neuroprotective drugs in improving functional outcomes of currently approved stroke treatments, specifically thrombectomy. Approximately 87% of strokes are ischemic in nature and occur due to an arterial occlusion [83](#sct312521-bib-0083){ref-type="ref"}. The most common approach to endovascular revascularization of large vessel occlusion (LVO) is stent retriever thrombectomy [84](#sct312521-bib-0084){ref-type="ref"}. Once a stent is deployed at the occlusion site, the clot becomes engaged and entrapped within the struts of the device, allowing subsequent withdrawal of both the stent and clot as a single unit. Stent retriever thrombectomy is currently recommended in patients with acute ischemic stroke from LVO [85](#sct312521-bib-0085){ref-type="ref"}. However, the risk of excessive bleeding is inherent with thrombectomy, necessitating the need for adjunctive treatments to minimize such adverse effect. The NIH SPAN program acknowledges the transient middle cerebral artery occlusion (tMCAO) as the standardized and validated model of stroke. By subsequently adding aging and other comorbidities to this tMCAO model and by enlisting multiple established laboratories (with solid track record of publications on the use of this MCAO model), a much more stringent platform will be in place to test therapeutics for translation into clinical application. The anticipated six SPAN sites will be identified and tasked to work closely together under the guidance of a coordinating center consisting of key thought leaders in stroke and neuroprotection, epitomizing the collaborative spirit of STEPS and STAIR consortia. Not too long ago, big pharmaceutical companies have remained on the sidelines from supporting stroke therapeutics, primarily due to the bleak outlook that the disease is treatable with neuroprotective drugs beyond thrombolytic agent tPA or mechanical thrombectomy. Now we have reached the crossroad of identifying a neuroprotective drug, not as a stand‐alone but as an adjunct to thrombectomy. One can envision stem cells as biologics [86](#sct312521-bib-0086){ref-type="ref"} operating as pharmacologic‐like agents as noted above, which may similarly be combined with thrombectomy. As noted above, stem cells may secrete a cocktail of therapeutic growth factors that collectively can induce regenerative processes [87](#sct312521-bib-0087){ref-type="ref"}, [88](#sct312521-bib-0088){ref-type="ref"} which may aid the neurovascular unit to respond better to thrombectomy.

So are we there yet? The recent failures of stem cell transplantation to reach efficacy in stroke clinical trials (MAPC and SB623) appear to set the bar much higher before we can replace the current designation of "experimental treatment" to "treatment option" for stem cell therapy (Figure [1](#sct312521-fig-0001){ref-type="fig"}). At the very least, a redesign of ongoing trials is needed to reconcile the disconnect between the laboratory and the clinical stem cell transplant protocols. A much narrower treatment window (i.e., transplantation within 36 hours of stroke onset) has now been indicated for the second MAPC clinical trial in acute ischemic stroke patients [60](#sct312521-bib-0060){ref-type="ref"}. A cell dosage closer to the preclinical dose‐approximated 56 million cells will likely need to be pursued with a new SB623 clinical trial for chronic stroke patients. Unfortunately, the long wait is not yet over. A collaborative effort and a commitment to basic science represent critical lab‐to‐clinic translational enabling factors toward a safe and effective stem cell therapy for stroke.

![Lab‐to‐clinic translational hurdles in stem cell therapy for stroke. Several factors enable the ascent of stem cell therapy at the basic science, translational, and clinical levels. Tissue sources for stem cell transplantation include fetal cells, iPSCs, ESCs, and adult tissue‐derived cells such as bone marrow MSCs. At the basic science level, stemness and underlying mechanisms of stem cells need to be probed. At the translational level, the transplant regimen needs to be optimized. At the clinical level, the safety and efficacy of the transplanted cells must be ensured, with the efficacy readouts remaining elusive in recent clinical trials. Abbreviations: ESCs, embryonic stem cells; iPSCs, induced pluripotent stem cells; MSCs, mesenchymal stem cells.](SCT3-8-983-g001){#sct312521-fig-0001}
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